Clene Announces Multi-Tranche Financing to Extend Cash Runway

Clene ( (CLNN) ) just unveiled an update.

On January 8, 2026, Clene Inc. entered into securities purchase agreements with institutional, existing and insider investors for a registered direct offering structured in three tranches totaling more than $28 million in potential gross proceeds, anchored by an initial sale of 928,333 common shares and accompanying Series A and Series B warrants at $6.50 per unit, which closed on January 13, 2026 and raised roughly $6 million. The financing, arranged on a best-efforts basis by BTIG, LLC, is expected to extend Clene’s cash runway into the third quarter of 2026 from the first tranche, with additional proceeds from the exercise of Series A and Series B warrants potentially funding the company through the end of 2026 and into early 2027 to support clinical development, regulatory activities, and potential commercialization of CNM-Au8 in ALS; the deal also includes issuance restrictions, director lock-ups, and contingent warrant pricing that ties higher exercise prices and call provisions to future FDA milestones and Clene’s share price performance.

The most recent analyst rating on (CLNN) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.

Spark’s Take on CLNN Stock

According to Spark, TipRanks’ AI Analyst, CLNN is a Neutral.

Overall score is weighed down primarily by weak financial performance (low revenue scale, heavy losses/cash burn, and negative equity). Technicals also remain bearish with price below key moving averages and negative MACD. Offsetting factors include positive corporate updates around biomarker data and an upcoming FDA meeting, but these are not yet de-risking enough to overcome the current financial profile.

To see Spark’s full report on CLNN stock, click here.

More about Clene

Clene Inc., based in Salt Lake City with R&D and manufacturing operations in Maryland, is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. Its lead investigational product, CNM-Au8, is an oral suspension of gold nanocrystals designed to enhance cellular energy production, support neuroprotection and remyelination, and improve survival and function of central nervous system cells.

Average Trading Volume: 173,801

Technical Sentiment Signal: Strong Sell

Current Market Cap: $66.09M

For a thorough assessment of CLNN stock, go to TipRanks’ Stock Analysis page.